SLC6A4 and movement disorder: Parkinson’s disease and other movement disorders are linked to dysregulation of dopaminergic neurotransmission (Cramb et al., 2023), while NMDA, as an excitatory neurotransmitter, serves as a biomarker of neuronal integrity (Foerster et al., 2013), SERT agonists have been shown to alleviate involuntary movements in Parkinson’s patients (Pagano et al., 2017).